

Mark J Ratain

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2844377/publications.pdf>

Version: 2024-02-01

105
papers

2,530
citations

230014

27
h-index

286692

43
g-index

109
all docs

109
docs citations

109
times ranked

3340
citing authors

#	ARTICLE	IF	CITATIONS
1	Pharmacokinetic Simulation Analysis of Less Frequent Nivolumab and Pembrolizumab Dosing: Pharmacoeconomic Rationale for Dose Deescalation. <i>Journal of Clinical Pharmacology</i> , 2022, 62, 532-540.	1.0	14
2	Dose Optimization of Pembrolizumab: Less May Be More. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 111, 993-993.	2.3	3
3	Alternative trastuzumab dosing strategies in HER2-positive early breast cancer are associated with patient out-of-pocket savings. <i>Npj Breast Cancer</i> , 2022, 8, 32.	2.3	10
4	Lorlatinib Exposed: A Far From Optimal Dose. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 111, 1195-1196.	2.3	2
5	Lurbinectedin-induced thrombocytopenia: the role of body surface area. <i>Cancer Chemotherapy and Pharmacology</i> , 2022, , 1.	1.1	0
6	Two polymorphic gene loci associated with treprostinil dose in pulmonary arterial hypertension. <i>Pharmacogenetics and Genomics</i> , 2022, Publish Ahead of Print, .	0.7	1
7	Subcutaneous Atezolizumab: A Jab Without a Benefit. <i>Clinical Pharmacology in Drug Development</i> , 2022, 11, 134-135.	0.8	1
8	Oncology Drug Prescribing: The Influences of Greed and Fear. <i>JCO Oncology Practice</i> , 2022, 18, e1384-e1387.	1.4	3
9	Accelerated Approval of Anticancer Drugs: Lessons Learned From the Example of Olaratumab. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 110, 29-31.	2.3	3
10	Oncologyâ€™s â€œHockey Stickâ€•Moment for the Cost of Cancer Drugsâ€”The Climate Is About to Change. <i>JAMA Oncology</i> , 2021, 7, 25.	3.4	12
11	Ibrutinibâ€™s Cardiotoxicityâ€”An Opportunity for Postmarketing Regulation. <i>JAMA Oncology</i> , 2021, 7, 177.	3.4	15
12	COVIDOSE: A Phase II Clinical Trial of Lowâ€•Dose Tocilizumab in the Treatment of Noncritical COVIDâ€•19 Pneumonia. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 688-696.	2.3	42
13	Genomic Analysis of Germline Variation Associated with Survival of Patients with Colorectal Cancer Treated with Chemotherapy Plus Biologics in CALGB/SWOG 80405 (Alliance). <i>Clinical Cancer Research</i> , 2021, 27, 267-275.	3.2	13
14	Near-Equivalence: Generating Evidence to Support Alternative Cost-Effective Treatments. <i>Journal of Clinical Oncology</i> , 2021, 39, 950-955.	0.8	28
15	The Right Dose: From Phase I to Clinical Practice. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2021, 41, 92-106.	1.8	3
16	Influence of N â€•acetyltransferase 2 gene polymorphisms on the in vitro metabolism of the epidermal growth factor receptor inhibitor rociletinib. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 4313-4322.	1.1	0
17	Designing Dose-Finding Phase I Clinical Trials: Top Questions That Should Be Discussed With Your Clinical Pharmacologist. <i>JCO Precision Oncology</i> , 2021, 5, 935-936.	1.5	2
18	The Abiraterone Dosing Chess Match With Johnson & Johnsonâ€”Back in Check. <i>JAMA Oncology</i> , 2021, 7, 827.	3.4	4

#	ARTICLE	IF	CITATIONS
19	Phase I Study of Stereotactic Body Radiotherapy plus Nivolumab and Urelumab or Cabiralizumab in Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2021, 27, 5510-5518.	3.2	23
20	Dose Optimization of Sotorasib: Is the US Food and Drug Administration Sending a Message?. <i>Journal of Clinical Oncology</i> , 2021, 39, 3423-3426.	0.8	25
21	Impact of <i>CYP2D6</i> Pharmacogenomic Status on Pain Control Among Opioid-Treated Oncology Patients. <i>Oncologist</i> , 2021, 26, e2042-e2052.	1.9	12
22	Impact and applicability of pharmacogenomics in rheumatology: an integrated analysis. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 1385-1393.	0.4	0
23	Combination therapy patents: a new front in evergreening. <i>Nature Biotechnology</i> , 2021, 39, 1504-1510.	9.4	8
24	Assessment of Patient Knowledge and Perceptions of Pharmacogenomics Before and After Using a Mock Results Patient Web Portal. <i>Clinical and Translational Science</i> , 2020, 13, 78-87.	1.5	8
25	A New Liver Expression Quantitative Trait Locus Map From 1,183 Individuals Provides Evidence for Novel Expression Quantitative Trait Loci of Drug Response, Metabolic, and Sex-Biased Phenotypes. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 107, 1383-1393.	2.3	20
26	Opportunities for using in silico-based extended dosing regimens for monoclonal antibody immune checkpoint inhibitors. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 1769-1777.	1.1	25
27	Applied Clinical Pharmacology in a Crisis: Interleukin-6 Axis Blockade and COVID-19. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 108, 425-427.	2.3	8
28	Weight-Based Dosing of Pembrolizumab Every 6 Weeks in the Time of COVID-19. <i>JAMA Oncology</i> , 2020, 6, 1694.	3.4	29
29	Genomewide Meta-Analysis Validates a Role for <i>S1PR1</i> in Microtubule Targeting Agent-Induced Sensory Peripheral Neuropathy. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 108, 625-634.	2.3	25
30	Optimal Sampling Strategies for Irinotecan (CPT-11) and its Active Metabolite (SN-38) in Cancer Patients. <i>AAPS Journal</i> , 2020, 22, 59.	2.2	4
31	Interventional Pharmacoeconomics: A Novel Mechanism for Unlocking Value. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 108, 487-493.	2.3	33
32	Implementation of pharmacogenomic testing in oncology care (PhOCus): study protocol of a pragmatic, randomized clinical trial. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592097411.	1.4	12
33	Genomic Heterogeneity Within Individual Prostate Cancer Foci Impacts Predictive Biomarkers of Targeted Therapy. <i>European Urology Focus</i> , 2019, 5, 416-424.	1.6	20
34	Clinical and Genome-Wide Analysis of Serum Platinum Levels after Cisplatin-Based Chemotherapy. <i>Clinical Cancer Research</i> , 2019, 25, 5913-5924.	3.2	16
35	Enhancing the Visibility and Prestige of Clinical Pharmacology as a Medical Subspecialty. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 106, 914-915.	2.3	0
36	Prolonged Pharmacokinetic Interaction Between Capecitabine and a CYP2C9 Substrate, Celecoxib. <i>Journal of Clinical Pharmacology</i> , 2019, 59, 1632-1640.	1.0	8

#	ARTICLE	IF	CITATIONS
37	A Cost-Focused Alternative Cancer Medication Dispensing Strategy—Pack Splitting. <i>JAMA Oncology</i> , 2019, 5, 1691.	3.4	2
38	Alternative dosing regimens for atezolizumab: right dose, wrong frequency. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 84, 1153-1155.	1.1	20
39	The ImPre-SS Trial: Implementation of Point-of-Care Pharmacogenomic Decision Support in Perioperative Care. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 106, 1179-1183.	2.3	15
40	Interventional Pharmacoeconomics—A New Discipline for a Cost-Constrained Environment. <i>JAMA Oncology</i> , 2019, 5, 1097.	3.4	43
41	The Role of Early-Phase Design—Letter. <i>Clinical Cancer Research</i> , 2019, 25, 3190-3190.	3.2	1
42	Immunotherapy and the A2A Adenosine Receptor: A Confounding Brew. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 106, 498-500.	2.3	1
43	Precision and Accuracy in the Brave New World of Basket Trials. <i>JCO Precision Oncology</i> , 2019, 3, 1-5.	1.5	0
44	Essential Characteristics of Pharmacogenomics Study Publications. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 105, 86-91.	2.3	9
45	The Molecular Profiling Lottery: More Accuracy, Less Precision, and No Cost. <i>Clinical Cancer Research</i> , 2019, 25, 1136-1138.	3.2	5
46	A Pharmacogenetic Prediction Model of Progression-Free Survival in Breast Cancer using Genome-Wide Genotyping Data from CALGB 40502 (Alliance). <i>Clinical Pharmacology and Therapeutics</i> , 2019, 105, 738-745.	2.3	11
47	Clinical pharmacodynamic/exposure characterisation of the multikinase inhibitor ilorasertib (ABT-348) in a phase 1 dose-escalation trial. <i>British Journal of Cancer</i> , 2018, 118, 1042-1050.	2.9	27
48	Time Is Money: Optimizing the Scheduling of Nivolumab. <i>Journal of Clinical Oncology</i> , 2018, 36, 3074-3076.	0.8	42
49	Do Patients With Advanced Cancer Have the Ability to Make Informed Decisions for Participation in Phase I Clinical Trials?. <i>Journal of Clinical Oncology</i> , 2018, 36, 2483-2491.	0.8	17
50	Prospective International Randomized Phase II Study of Low-Dose Abiraterone With Food Versus Standard Dose Abiraterone In Castration-Resistant Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 1389-1395.	0.8	137
51	A pharmacodynamic study of sirolimus and metformin in patients with advanced solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 82, 309-317.	1.1	12
52	Analyzing the clinical actionability of germline pharmacogenomic findings in oncology. <i>Cancer</i> , 2018, 124, 3052-3065.	2.0	14
53	Identification of a Genomic Region between <i>SLC29A1</i> and <i>HSP90AB1</i> Associated with Risk of Bevacizumab-Induced Hypertension: CALGB 80405 (Alliance). <i>Clinical Cancer Research</i> , 2018, 24, 4734-4744.	3.2	14
54	Simplifying the use of pharmacogenomics in clinical practice: Building the genomic prescribing system. <i>Journal of Biomedical Informatics</i> , 2017, 75, 110-121.	2.5	38

#	ARTICLE	IF	CITATIONS
55	Burdensome Research Procedures in Trials: Why Less Is More. Journal of the National Cancer Institute, 2017, 109, .	3.0	17
56	A randomized phase I trial of nanoparticle albumin-bound paclitaxel with or without mifepristone for advanced breast cancer. SpringerPlus, 2016, 5, 947.	1.2	29
57	Pharmacogenetic Discovery in CALGB (Alliance) 90401 and Mechanistic Validation of a <i>VAC14</i> Polymorphism that Increases Risk of Docetaxel-Induced Neuropathy. Clinical Cancer Research, 2016, 22, 4890-4900.	3.2	46
58	Analysis of Impact of Post-Treatment Biopsies in Phase I Clinical Trials. Journal of Clinical Oncology, 2016, 34, 369-374.	0.8	35
59	The Impact of Industry on Oncology Research and Practice. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2015, , 130-137.	1.8	14
60	Evidence for Clinical Implementation of Pharmacogenomics in Cardiac Drugs. Mayo Clinic Proceedings, 2015, 90, 716-729.	1.4	44
61	<i>UGT1A</i> and <i>UGT2B</i> Genetic Variation Alters Nicotine and Nitrosamine Glucuronidation in European and African American Smokers. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 94-104.	1.1	27
62	First-in-human, phase I study of elisidepsin (PM02734) administered as a 30-min or as a 3-hour intravenous infusion every three weeks in patients with advanced solid tumors. Investigational New Drugs, 2015, 33, 901-910.	1.2	12
63	Glucuronidation of OTS167 in Humans Is Catalyzed by UDP-Glucuronosyltransferases UGT1A1, UGT1A3, UGT1A8, and UGT1A10. Drug Metabolism and Disposition, 2015, 43, 928-935.	1.7	12
64	Serum C-Telopeptide Collagen Crosslinks and Plasma Soluble VEGFR2 as Pharmacodynamic Biomarkers in a Trial of Sequentially Administered Sunitinib and Cilengitide. Clinical Cancer Research, 2015, 21, 5092-5099.	3.2	3
65	<i>In vitro</i> glucuronidation of aprepitant: a moderate inhibitor of UGT2B7. Xenobiotica, 2015, 45, 990-998.	0.5	8
66	Loss of Heterozygosity at the CYP2D6 Locus in Breast Cancer: Implications for Germline Pharmacogenetic Studies. Journal of the National Cancer Institute, 2015, 107, .	3.0	37
67	Identification of a Variant in <i>KDR</i> Associated with Serum VEGFR2 and Pharmacodynamics of Pazopanib. Clinical Cancer Research, 2015, 21, 365-372.	3.2	29
68	Design of Phase I Combination Trials: Recommendations of the Clinical Trial Design Task Force of the NCI Investigational Drug Steering Committee. Clinical Cancer Research, 2014, 20, 4210-4217.	3.2	56
69	Re: Concordance Between CYP2D6 Genotypes Obtained From Tumor-Derived and Germline DNA. Journal of the National Cancer Institute, 2014, 106, .	3.0	4
70	First-In-Human Phase I Study of Lurbinectedin (PM01183) in Patients with Advanced Solid Tumors. Clinical Cancer Research, 2014, 20, 2205-2214.	3.2	74
71	Redefining the primary objective of phase I oncology trials. Nature Reviews Clinical Oncology, 2014, 11, 503-504.	12.5	39
72	Flushing Oral Oncology Drugs Down the Toilet. Journal of Clinical Oncology, 2011, 29, 3958-3959.	0.8	47

#	ARTICLE	IF	CITATIONS
73	Inconsistent Labeling of Food Effect for Oral Agents across Therapeutic Areas: Differences between Oncology and Non-Oncology Products. <i>Clinical Cancer Research</i> , 2010, 16, 4446-4451.	3.2	67
74	Individualizing Dosing of Irinotecan. <i>Clinical Cancer Research</i> , 2010, 16, 371-372.	3.2	16
75	Optimising the design of phase II oncology trials: The importance of randomisation. <i>European Journal of Cancer</i> , 2009, 45, 275-280.	1.3	119
76	The Value Meal: How to Save \$1,700 Per Month or More on Lapatinib. <i>Journal of Clinical Oncology</i> , 2007, 25, 3397-3398.	0.8	86
77	From Bedside to Bench to Bedside to Clinical Practice: An Odyssey with Irinotecan: Fig. 1.. <i>Clinical Cancer Research</i> , 2006, 12, 1658-1660.	3.2	46
78	Phase I Study of XK469R (NSC 698215), a Quinoxaline Phenoxypropionic Acid Derivative, in Patients with Refractory Hematological Malignancies.. <i>Blood</i> , 2006, 108, 1952-1952.	0.6	0
79	Pharmacogenomics of Deferiprone Metabolism.. <i>Blood</i> , 2005, 106, 2703-2703.	0.6	4
80	Finding the right dose. <i>Clinical Advances in Hematology and Oncology</i> , 2003, 1, 517-8, 531.	0.3	4
81	Body surface area as a determinant of pharmacokinetics and drug dosing. , 2001, 19, 171-177.		184
82	Screening for Sources of Interindividual Pharmacokinetic Variability in Anticancer Drug Therapy: Utility of Population Analysis. <i>Cancer Investigation</i> , 2001, 19, 57-64.	0.6	7
83	Phase I and Pharmacokinetic Trial of Gemcitabine in Patients With Hepatic or Renal Dysfunction: Cancer and Leukemia Group B 9565. <i>Journal of Clinical Oncology</i> , 2000, 18, 2780-2787.	0.8	177
84	Development of a schedule-dependent population pharmacodynamic model for rhizoxin without quantitation of plasma concentrations. <i>Cancer Chemotherapy and Pharmacology</i> , 2000, 45, 489-494.	1.1	2
85	Pharmacogenetics. <i>Clinical Pharmacokinetics</i> , 2000, 39, 315-325.	1.6	39
86	A phase I study of oral uracil/ftorafur (UFT) plus leucovorin and bis-acetato-ammine-dichloro-cyclohexylamine-platinum IV (JM-216) each given over 14 days every 28 days. <i>Cancer Chemotherapy and Pharmacology</i> , 1999, 43, 385-388.	1.1	17
87	A Phase II Trial of Oral Trimethylcolchicinic Acid in Patients with Hormone Refractory Prostate Cancer. <i>Prostate Journal</i> , 1999, 1, 195-202.	0.2	1
88	A Phase I study of raltitrexed and paclitaxel given every 3 weeks to patients with solid tumors. <i>Cancer</i> , 1999, 86, 528-532.	2.0	4
89	5-Fluorouracil Pharmacokinetics: Causes for Variability and Strategies for Modulation in Cancer Chemotherapy. <i>Cancer Investigation</i> , 1999, 17, 494-506.	0.6	37
90	Granulocyte-macrophage-colony stimulating factor in metastatic renal cell carcinoma. , 1998, 82, 1352-1358.		33

#	ARTICLE	IF	CITATIONS
91	Phase I clinical and pharmacokinetic study of oral 9-aminocamptothecin (NSC-603071). <i>Cancer Chemotherapy and Pharmacology</i> , 1998, 42, 84-87.	1.1	23
92	Evaluation of neuropathy in patients on suramin treatment. <i>Muscle and Nerve</i> , 1997, 20, 83-91.	1.0	27
93	Phase I study of escalating doses of mitoxantrone and paclitaxel with granulocyte-macrophage colony stimulating factor support. , 1996, 77, 2308-2312.		4
94	Mineralocorticoid insufficiency due to suramin therapy. , 1996, 78, 2411-2420.		23
95	Encephalopathy is the dose-limiting toxicity of intravenous hepsulfam: results of a phase I trial in patients with advanced hematological malignancies. <i>Cancer Chemotherapy and Pharmacology</i> , 1995, 36, 204-210.	1.1	1
96	Phase I Trial of a Genetically Engineered Interleukin-2 Fusion Toxin (DAB ₄₈₆ IL-2) as a 6 Hour Intravenous Infusion in Patients with Hematologic Malignancies. <i>Leukemia and Lymphoma</i> , 1994, 14, 257-262.	0.6	22
97	Prognostic factors for survival in patients treated in phase I clinical trials. <i>Cancer</i> , 1994, 74, 1965-1973.	2.0	58
98	Sequential therapy with dacarbazine and carmustine: a phase I study. <i>Cancer Chemotherapy and Pharmacology</i> , 1994, 34, 509-514.	1.1	9
99	Letter to the editors. <i>Cancer Chemotherapy and Pharmacology</i> , 1994, 34, 535-536.	1.1	0
100	Five-day infusional fluorodeoxyuridine with oral leucovorin and escalating doses of interferon alpha-2b: a phase I study. <i>Cancer Chemotherapy and Pharmacology</i> , 1993, 32, 347-352.	1.1	2
101	Modulation of vinblastine resistance with cyclosporine: A phase I study. <i>Clinical Pharmacology and Therapeutics</i> , 1993, 54, 421-429.	2.3	40
102	Clinical Pharmacokinetics of High-Dose Leucovorin Calcium After Intravenous and Oral Administration. <i>Journal of the National Cancer Institute</i> , 1990, 82, 1411-1415.	3.0	40
103	A randomized study of inpatient versus outpatient continuous infusion chemotherapy for patients with locally advanced head and neck cancer. <i>Cancer</i> , 1989, 63, 30-36.	2.0	42
104	Flow cytometry in hairy cell leukemia before and during interferon alfa-2b therapy. <i>Cancer</i> , 1987, 59, 1987-1991.	2.0	8
105	Pharmacogenomics of Chemotherapeutic Agents in Cancer Treatment. , 0, , 283-309.		1